NEW YORK (GenomeWeb News) – The US Food and Drug Administration today issued a draft guidance for industry and FDA staff covering how in vitro diagnostic devices for human papillomaviruses should be measured and handled for analytical and clinical performance.

FDA's Center for Devices and Radiological Health released the guidance today for comment purposes, providing a set of recommendations for the types of studies of IVDs that are intended to detect and differentiate HPV strains and are used in conjunction with cervical cancer screening.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.